Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing nelfinavir.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gathe, Joseph, M.D.
• Treatments: Amprenavir; Ritonavir

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are 18 years of age or older.

• Are HIV-positive.

• Have a viral load (level of HIV in the body) of more than 1,000 copies/ml.

• Have had more than 12 weeks of prior anti-HIV drug treatment.

• Have failed a previous anti-HIV treatment containing nelfinavir as the only protease inhibitor.

• Are responsive to Agenerase.

• Are able to follow study requirements.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Are intolerant to ritonavir (an anti-HIV drug).

• Have or have had problems with absorption.

• Have liver disease or damage.

• Have pancreatic disease or damage.

• Have taken any protease inhibitor other than nelfinavir.

• Are receiving investigational drugs or devices from another study.

• Are pregnant or breast-feeding.

• Currently use triazolam, astemizole, ergot medications, cisapride, midazolam, bepridil, rifampin, terfenadine, or pimozide.

• Have a bleeding disorder.

• Have previously been treated with Agenerase.

• Are receiving nonnucleosides.